^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Gazyva (obinutuzumab)

    i
    Other names: RG 7159, RG7159, RO5072759, GA-101, R-7159, RG-7159, RO-5072759, GA101, R 7159, RO 5072759, GA 101, R7159
    Company:
    Biogen, Nippon Shinyaku, Roche
    Drug class:
    CD20 inhibitor
    Related drugs:
    1d
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    2d
    Radio-GLO: Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Olivia Newton-John Cancer Research Institute
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL4 (Interleukin 4)
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    5d
    Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. (PubMed, Cancer Med)
    In real-world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first-line therapy in patients with TP53 wild-type CLL.
    Journal • Real-world evidence • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    9d
    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, National Cancer Institute (NCI) | N=55 --> 34 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)
    10d
    HO158: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial) (2022-502808-72-00)
    P1/2, N=85, Active, not recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    10d
    2023/ABM/01/00072: A study aimed at Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC) (2024-513917-11-01)
    P1/2, N=36, Not yet recruiting, Uniwersytet Medyczny W Lublinie
    New P1/2 trial
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Darzalex (daratumumab)
    12d
    Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    TP53 (Tumor protein P53)
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • Columvi (glofitamab-gxbm)
    13d
    The Clinical Application Study of Obinutuzumab in Pediatric Refractory Nephrotic Syndrome (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Children's Hospital of Chongqing Medical University
    New trial
    |
    Gazyva (obinutuzumab)
    13d
    PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis (clinicaltrials.gov)
    P4, N=150, Recruiting, Aurinia Pharmaceuticals Inc.
    New P4 trial
    |
    Gazyva (obinutuzumab)
    15d
    UPCC 48420: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov)
    P2, N=23, Recruiting, Abramson Cancer Center at Penn Medicine | N=42 --> 23
    Enrollment change
    |
    Gazyva (obinutuzumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    16d
    Case Report: Neurolymphomatosis of the sciatic nerve as a presentation of relapsed diffuse large B-cell lymphoma. (PubMed, Front Oncol)
    A 71-year-old man with systemic diffuse large B-cell lymphoma (DLBCL), histologically confirmed by gastric biopsy, developed progressive left-leg neuropathic pain, numbness, and foot drop during rituximab maintenance after achieving complete remission (CR)...Given the patient's age and risk of neurotoxicity, treatment with cyclophosphamide preconditioning followed by glofitamab plus obinutuzumab achieved rapid clinical improvement and partial remission (PR) on imaging...In this case, nerve US played a central role by demonstrating the characteristic "fried egg sign," localizing the lesion, and enabling US-CNB for tissue confirmation, while contrast-enhanced MRI and whole-body ^18F-FDG PET/CT provided complementary information on neural involvement and overall disease extent. An ultrasound-centered multimodal approach may help shorten time to diagnosis and facilitate timely treatment and neurological recovery.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • cyclophosphamide • Columvi (glofitamab-gxbm)
    21d
    A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=96, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Columvi (glofitamab-gxbm)